[go: up one dir, main page]

CL2016001151A1 - Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos. - Google Patents

Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.

Info

Publication number
CL2016001151A1
CL2016001151A1 CL2016001151A CL2016001151A CL2016001151A1 CL 2016001151 A1 CL2016001151 A1 CL 2016001151A1 CL 2016001151 A CL2016001151 A CL 2016001151A CL 2016001151 A CL2016001151 A CL 2016001151A CL 2016001151 A1 CL2016001151 A1 CL 2016001151A1
Authority
CL
Chile
Prior art keywords
treatment
proliferative disorders
purine derivatives
substituted purine
substituted
Prior art date
Application number
CL2016001151A
Other languages
English (en)
Inventor
Hengmiao Cheng
John Charles Kath
Asako Nagata
Sajiv Krishnan Nair
Simon Paul Planken
Douglas Carl Behenna
Sujin Cho-Schultz
Jr Theodore Otto Johnson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CL2016001151A1 publication Critical patent/CL2016001151A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DERIVADOS DE PURINA 2,6-SUSTITUIDOS; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y SU USO PARA EL TRATAMIENTO DEL CANCER Y PARA TRATAR EL CRECIMIENTO CELULAR ANORMAL EN UN MAMIFERO.
CL2016001151A 2013-11-21 2016-05-13 Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos. CL2016001151A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361907322P 2013-11-21 2013-11-21

Publications (1)

Publication Number Publication Date
CL2016001151A1 true CL2016001151A1 (es) 2017-01-06

Family

ID=52004011

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001151A CL2016001151A1 (es) 2013-11-21 2016-05-13 Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.

Country Status (39)

Country Link
US (1) US9290496B2 (es)
EP (1) EP3071570B1 (es)
JP (2) JP6166845B2 (es)
KR (1) KR101919672B1 (es)
CN (1) CN105916853B (es)
AP (1) AP2016009219A0 (es)
AR (1) AR098492A1 (es)
AU (1) AU2014351433B2 (es)
CA (1) CA2931034C (es)
CL (1) CL2016001151A1 (es)
CR (1) CR20160236A (es)
CU (1) CU24402B1 (es)
CY (1) CY1120478T1 (es)
DK (1) DK3071570T3 (es)
DO (1) DOP2016000115A (es)
EA (1) EA029842B1 (es)
ES (1) ES2681799T3 (es)
GE (2) GEP20186878B (es)
GT (1) GT201600091A (es)
HR (1) HRP20181036T1 (es)
HU (1) HUE039858T2 (es)
IL (1) IL245698B (es)
LT (1) LT3071570T (es)
MA (1) MA39043B1 (es)
MD (1) MD20160053A2 (es)
MX (1) MX2016006397A (es)
MY (1) MY184433A (es)
NI (1) NI201600072A (es)
PE (1) PE20160885A1 (es)
PH (1) PH12016500911A1 (es)
PL (1) PL3071570T3 (es)
PT (1) PT3071570T (es)
RS (1) RS57537B1 (es)
SI (1) SI3071570T1 (es)
TN (1) TN2016000188A1 (es)
TW (1) TWI538913B (es)
UA (1) UA115388C2 (es)
UY (1) UY35845A (es)
WO (1) WO2015075598A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CA2924362C (en) * 2013-09-18 2018-12-18 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of btk and/or jak3 kinases
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20180201614A1 (en) * 2015-05-12 2018-07-19 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
CN109937039A (zh) * 2016-09-30 2019-06-25 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂
WO2018091999A1 (en) 2016-11-16 2018-05-24 Pfizer Inc. Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
BR112019012682A2 (pt) 2016-12-23 2019-12-17 Arvinas Operations Inc moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
CN111051304B (zh) 2017-03-10 2022-12-27 辉瑞大药厂 作为LRRK2抑制剂的咪唑并[4,5-c]喹啉衍生物
CA3056027A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
WO2019241896A1 (en) 2018-06-22 2019-12-26 The Royal Institution For The Advancement Of Learning/Mcgill University Purine compounds and method for the treatment of cancer
KR20200105631A (ko) * 2019-02-28 2020-09-08 보로노이바이오 주식회사 N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 약학적 조성물
KR102841446B1 (ko) * 2020-05-20 2025-07-31 티와이케이 메디슨즈, 인코포레이티드 Ret 키나아제 억제제로 사용되는 화합물 및 이의 용도
US12115157B2 (en) 2021-09-14 2024-10-15 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CA2260058A1 (en) 1996-07-13 1998-01-22 Kathryn Jane Smith Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
ATE217315T1 (de) 1996-07-18 2002-05-15 Pfizer Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren
US6790958B2 (en) 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6794390B2 (en) 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
BR9714266A (pt) 1997-01-06 2000-04-18 Pfizer Derivados de sulfona cìclicos.
IL131042A0 (en) 1997-02-03 2001-01-28 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives
BR9807824A (pt) 1997-02-07 2000-03-08 Pfizer Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
WO1998034918A1 (en) 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc ANGIOGENESIS INHIBITORS
AU735127B2 (en) 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
KR100446363B1 (ko) 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
EA005032B1 (ru) 1998-05-29 2004-10-28 Сьюджен, Инк. Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP4044839B2 (ja) 2000-06-22 2008-02-06 ファイザー・プロダクツ・インク 異常細胞増殖を治療するための置換２環式誘導体
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
WO2003009852A1 (en) 2001-07-24 2003-02-06 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2463563A1 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
US6949644B2 (en) 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
WO2005016268A2 (en) 2003-08-08 2005-02-24 Mitochroma Research, Inc. Alimentary compositions and methods for metabolic modulation
SG145748A1 (en) 2003-08-15 2008-09-29 Irm Llc 6-substituted anilino purines as rtk inhibitors
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
GB0502573D0 (en) 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US20070253896A1 (en) 2006-02-07 2007-11-01 Conforma Therapeutics Corporation 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors
EP2008210A1 (en) 2006-03-15 2008-12-31 Csir Modulation of phosphoryl transferase activity of glutamine synthetase
ES2402907T3 (es) 2006-10-19 2013-05-10 Genzyme Corporation Roscovitina para el tratamiento de ciertas enfermedades quísticas
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
KR20090112732A (ko) 2007-01-26 2009-10-28 아이알엠 엘엘씨 플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물
US8404674B2 (en) * 2007-03-07 2013-03-26 Boehringer Ingelheim International Gmbh Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
BRPI0814939A2 (pt) 2007-08-10 2015-01-27 Glaxosmithkline Llc Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
US20100197914A1 (en) 2007-10-17 2010-08-05 Robin Alec Fairhurst Purine Derivatives as Adenosine Al Receptor Ligands
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
EP2312945A4 (en) 2008-08-13 2012-05-09 Merck Sharp & Dohme PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2010034740A1 (en) * 2008-09-23 2010-04-01 Palau Pharma, S.A. (r)-3-(n,n-dimethylamino)pyrrolidine derivatives
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
EP2440559B1 (en) * 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
FR2945747A1 (fr) * 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
WO2011156889A1 (en) 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
EP2585464A2 (en) 2010-06-22 2013-05-01 University Of Central Florida Research Foundation, Inc. Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
AU2011315831B2 (en) * 2010-10-14 2015-01-22 Takeda Pharmaceutical Company Limited Methods for inhibiting cell proliferation in EGFR-driven cancers
WO2012061303A1 (en) * 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012064706A1 (en) * 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
EA201391626A1 (ru) * 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
US8762299B1 (en) 2011-06-27 2014-06-24 Google Inc. Customized predictive analytical model training
UA110259C2 (uk) * 2011-09-22 2015-12-10 Пфайзер Інк. Похідні піролопіримідину і пурину
CN103159742B (zh) 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
WO2013106792A1 (en) 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
EP2968336A2 (en) 2013-03-14 2016-01-20 Pfizer Inc. Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
IL245698B (en) 2019-11-28
TWI538913B (zh) 2016-06-21
CY1120478T1 (el) 2019-07-10
CR20160236A (es) 2016-07-22
UY35845A (es) 2015-06-30
CN105916853B (zh) 2018-07-27
EA201600337A1 (ru) 2016-10-31
MA39043A1 (fr) 2018-01-31
PL3071570T3 (pl) 2018-10-31
HRP20181036T1 (hr) 2018-08-24
TN2016000188A1 (fr) 2017-10-06
CA2931034C (en) 2019-01-08
TW201524979A (zh) 2015-07-01
EP3071570B1 (en) 2018-06-20
GEAP201814151A (en) 2018-03-26
KR101919672B1 (ko) 2018-11-16
EP3071570A1 (en) 2016-09-28
AU2014351433A1 (en) 2016-06-02
KR20160077217A (ko) 2016-07-01
US20150141402A1 (en) 2015-05-21
EA029842B1 (ru) 2018-05-31
MY184433A (en) 2021-04-01
MX2016006397A (es) 2016-08-01
NI201600072A (es) 2016-08-09
PH12016500911A1 (en) 2016-06-20
CA2931034A1 (en) 2015-05-28
JP2016537382A (ja) 2016-12-01
WO2015075598A1 (en) 2015-05-28
CU24402B1 (es) 2019-05-03
DOP2016000115A (es) 2016-07-15
CN105916853A (zh) 2016-08-31
MA39043B1 (fr) 2018-09-28
JP2017214390A (ja) 2017-12-07
DK3071570T3 (en) 2018-08-13
AU2014351433B2 (en) 2017-08-24
AR098492A1 (es) 2016-06-01
RS57537B1 (sr) 2018-10-31
SI3071570T1 (sl) 2018-12-31
GEP20186878B (en) 2018-07-10
MD20160053A2 (ro) 2016-10-31
PE20160885A1 (es) 2016-09-11
LT3071570T (lt) 2018-08-10
AP2016009219A0 (en) 2016-05-31
US9290496B2 (en) 2016-03-22
ES2681799T3 (es) 2018-09-17
IL245698A0 (en) 2016-08-02
PT3071570T (pt) 2018-08-01
GT201600091A (es) 2017-11-09
CU20160073A7 (es) 2016-10-28
JP6166845B2 (ja) 2017-07-19
HUE039858T2 (hu) 2019-02-28
UA115388C2 (uk) 2017-10-25

Similar Documents

Publication Publication Date Title
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
MX380829B (es) Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
CL2015001437A1 (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2016000922A1 (es) Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
MX2016007410A (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.